Latest News

Post–Mohs Surgery Opioid Prescribing More Common in Some Patient Groups


 

FROM ACMS 2024

Long-Term Consequences

The authors also looked at the longer-term consequences of postop opioid use. “Nearly one in three patients who were prescribed opioids needed subsequent prescriptions down the line,” said Dr. Lauck.

From 3 months to 5 years after surgery, patients who received postsurgical opioids were at significantly higher risk for not only subsequent oral opioid prescription but also opiate abuse, any substance abuse, overdose by opioid narcotics, constipation, and chronic pain. “An opioid prescription may confer further risks of longitudinal complications of chronic opioid use,” he concluded.

Commenting on the study, Jesse M. Lewin, MD, chief of Mohs micrographic and dermatologic surgery at Icahn School of Medicine at Mount Sinai, New York City, noted an important finding of this study was the long-term sequelae of patients who did receive postop opioids.

“This is striking given that postsurgical opiate prescriptions are for short durations and limited number of pills,” he told this news organization. “This study highlights the potential danger of even short course of opiates and should serve as a reminder to dermatologic surgeons to be judicious about opiate prescribing.”

Dr. Lauck and Dr. Lewin had no disclosures.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Study suggests narrow excision margins safe in early melanoma resection
MDedge Hematology and Oncology
Controlled hyperthermia: Novel treatment of BCCs without surgery continues to be refined
MDedge Hematology and Oncology
Mohs surgery improves survival in early-stage Merkel cell carcinoma
MDedge Hematology and Oncology
Mohs surgery workforce continues to increase
MDedge Hematology and Oncology
Teledermatology follow-up after Mohs surgery gets a thumbs up from patients
MDedge Hematology and Oncology
Antibiotic prophylaxis may lower SSIs in skin cancer surgery
MDedge Hematology and Oncology
Study supports new NCCN classification for cutaneous squamous cell carcinoma
MDedge Hematology and Oncology
Mohs found to confer survival benefit in localized Merkel cell carcinoma
MDedge Hematology and Oncology
Incipient ulceration may affect prognosis in primary melanoma
MDedge Hematology and Oncology
Subcutaneous Antifibrinolytic Reduces Bleeding After Mohs Surgery
MDedge Hematology and Oncology